Identification of the transcriptional regulatory sequences of human calponin promoter and their use in targeting a conditionally replicating herpes vector to malignant human soft tissue and bone tumors.
The calponin (basic or h1) gene, normally expressed in maturated smooth muscle cells, is aberrantly expressed in a variety of human soft tissue and bone tumors. In this study, we show that expression of the calponin gene in human soft tissue and bone tumor cells is regulated at the transcriptional level by the sequence between positions -260 and -219 upstream of the translation initiation site. A novel conditionally replicating herpes simplex virus-1 vector (d12.CALP) in which the calponin promoter drives expression of ICP4, a major trans-activating factor for viral genes was constructed and tested as an experimental treatment for malignant human soft tissue and bone tumors. In cell culture, d12.CALP at low multiplicity of infection (0.001 plaque-forming unit/cell) selectively killed calponin-positive human synovial sarcoma, leiomyosarcoma, and osteosarcoma cells. For in vivo studies, 10 animals harboring SK-LMS-1 human leiomyosarcoma cells were randomly divided and treated twice on days 0 and 9 intraneoplastically with either 1 x 10(7) plaque-forming units of d12.CALP/100 mm(3) of tumor volume or with medium alone. The viral treatment group showed stable and significant inhibition of tumorigenicity with apparent cure in four of five mice by day 35. Replication of viral DNA demonstrated by PCR amplification and expression of the inserted LacZ gene visualized by 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside histochemistry was associated with oncolysis of d12.CALP-treated tumors, while sparing normal vascular smooth muscle cells. In mice harboring two SK-LMS-1 tumors, replication of d12.CALP was detected in a nontreated tumor distant from the site of virus inoculation. These results indicate that replication-competent virus vectors controlled by the calponin transcriptional regulatory sequence may be a new therapeutic strategy for treatment of malignant human soft tissue and bone tumors.
Yamamura
H
H
Department of Medicine, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1-3-3 Nakamichi, Higashinari-ku, Osaka City, Osaka 537-8511, Japan.
Hashio
M
M
Noguchi
M
M
Sugenoya
Y
Y
Osakada
M
M
Hirano
N
N
Sasaki
Y
Y
Yoden
T
T
Awata
N
N
Araki
N
N
Tatsuta
M
M
Miyatake
S I
SI
Takahashi
K
K
D000818:Animals; D001859:Bone Neoplasms / Q000235:genetics* / Q000628:therapy; D002135:Calcium-Binding Proteins / Q000235:genetics*; D002522:Chlorocebus aethiops; D004273:DNA, Neoplasm / Q000235:genetics*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000235:genetics; D006801:Humans; D007890:Leiomyosarcoma / Q000235:genetics / Q000628:therapy; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D008840:Microfilament Proteins; D010024:Osteoporosis / Q000235:genetics / Q000628:therapy; D011401:Promoter Regions, Genetic / Q000235:genetics*; D018139:Simplexvirus / Q000235:genetics; D012983:Soft Tissue Neoplasms / Q000235:genetics* / Q000628:therapy; D014158:Transcription, Genetic; D014407:Tumor Cells, Cultured; D014709:Vero Cells; D014779:Virus Replication; D023041:Xenograft Model Antitumor Assays; D000096985:Calponins
D002135:Calcium-Binding Proteins; D004273:DNA, Neoplasm; D008840:Microfilament Proteins; D000096985:Calponins